Literature DB >> 22999996

JTS-653 blocks afferent nerve firing and attenuates bladder overactivity without affecting normal voiding function.

Yoshihiro Kitagawa1, Masashi Wada, Tomokazu Kanehisa, Atsuko Miyai, Kenji Usui, Mariko Maekawa, Masahiro Sakata, Akira Matsuo, Mikio Hayashi, Mutsuyoshi Matsushita.   

Abstract

PURPOSE: We evaluated the role of TRPV1 in bladder overactivity based on afferent nerve firing and urodynamic parameters using the selective TRPV1 antagonist JTS-653.
MATERIALS AND METHODS: We evaluated the effects of JTS-653 on the increased pelvic nerve discharge and intravesical pressure induced by intravesical infusion of 100 μM capsaicin in anesthetized rats. The effects of JTS-653 on the urodynamic parameters of bladder overactivity induced by intravesical infusion of 30 nM resiniferatoxin or 0.2% acetic acid, or on normal bladder activity were evaluated by cystometry in conscious rats. The effects of JTS-653 on carbachol induced contraction were investigated using bladder muscle strips.
RESULTS: JTS-653 significantly suppressed the capsaicin induced increase in nerve discharge and intravesical pressure. Intravesical infusion of resiniferatoxin or acetic acid decreased the intercontraction interval and voided volume. JTS-653 significantly increased the intercontraction interval and voided volume in rats with resiniferatoxin or acetic acid induced bladder overactivity without affecting maximal voiding pressure. The antimuscarinic agent propiverine significantly decreased maximal voiding pressure but did not affect the intercontraction interval or voided volume in rats with acetic acid induced bladder overactivity. In normal rats JTS-653 showed no significant effects on the intercontraction interval, voided volume or maximal voiding pressure. JTS-653 did not affect carbachol induced contraction of the bladder muscle.
CONCLUSIONS: Our findings suggest that TRPV1 is involved in bladder overactivity via afferent nerve activation but it is not associated with normal voiding function. A TRPV1 antagonist would be a useful drug for bladder overactivity with a different pharmacological profile than antimuscarinic agents.
Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22999996     DOI: 10.1016/j.juro.2012.09.055

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

Review 1.  Report and Research Agenda of the American Geriatrics Society and National Institute on Aging Bedside-to-Bench Conference on Urinary Incontinence in Older Adults: A Translational Research Agenda for a Complex Geriatric Syndrome.

Authors:  Camille P Vaughan; Alayne D Markland; Phillip P Smith; Kathryn L Burgio; George A Kuchel
Journal:  J Am Geriatr Soc       Date:  2017-12-04       Impact factor: 5.562

Review 2.  Intravesical treatments of bladder pain syndrome/interstitial cystitis.

Authors:  Jochen Neuhaus; Thilo Schwalenberg
Journal:  Nat Rev Urol       Date:  2012-11-27       Impact factor: 14.432

3.  Neurophysiological modeling of bladder afferent activity in the rat overactive bladder model.

Authors:  Mahipal Choudhary; Els van Asselt; Ron van Mastrigt; Francesco Clavica
Journal:  J Physiol Sci       Date:  2015-03-18       Impact factor: 2.781

Review 4.  The TRPM8 channel as a potential therapeutic target for bladder hypersensitive disorders.

Authors:  Naoki Aizawa; Tomoe Fujita
Journal:  J Smooth Muscle Res       Date:  2022

Review 5.  Acute Intravesical Capsaicin for the Study of TRPV1 in the Lower Urinary Tract: Clinical Relevance and Potential for Innovation.

Authors:  Karl-Erik Andersson; Delphine Behr-Roussel; Pierre Denys; Francois Giuliano
Journal:  Med Sci (Basel)       Date:  2022-09-10

6.  Neonatal Bladder Irritation Is Associated With Vanilloid Receptor TRPV1 Expression in Adult Rats.

Authors:  Jee Soo Park; Hae Do Jung; Young Sam Cho; Mei Hua Jin; Chang Hee Hong
Journal:  Int Neurourol J       Date:  2018-09-28       Impact factor: 2.835

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.